• AbbVie added Phase 3 programs for ABBV-1480 with chemotherapy in first-line NSCLC and etentamig combinations in multiple myeloma.
• Etentamig monotherapy for third-line multiple myeloma is submitted for regulatory review, with approval anticipated in 2027.
• Rinvoq regulatory submissions for hidradenitis suppurativa and systemic lupus erythematosus are expected in 2027.
• Epkinly with R-CHOP in first-line DLBCL completed its Phase 3 readout; regulatory approval is anticipated in 2027.
• ABBV-243's Phase 1 inflammatory bowel disease program was discontinued.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.